The authors conclude PolyCore showed favorable in vitro biocompatibility versus icodextrin 7.5% and may represent a glucose-free bimodal strategy for PD; EXCITE will provide its first clinical assessment of safety and preliminary efficacy.
pubmed.ncbi.nlm.nih.gov/42847558/
